# Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

> **NCT05821192** · NA · UNKNOWN · sponsor: **Ou Bai, MD/PHD** · enrollment: 34 (estimated)

## Conditions studied

- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Dexamethasone
- **DRUG:** Cisplatin
- **DRUG:** PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05821192
- **Lead sponsor:** Ou Bai, MD/PHD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-23
- **Primary completion:** 2023-04-18
- **Final completion:** 2024-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821192, "Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05821192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*